184 related articles for article (PubMed ID: 33414260)
1. Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics.
Gunatilake S; Lodge D; Neville D; Jones T; Fogg C; Bassett P; Begum S; Kerley S; Marshall L; Glaysher S; Elliott S; Stores R; Bishop L; Chauhan A
BMJ Open Respir Res; 2021 Jan; 8(1):. PubMed ID: 33414260
[TBL] [Abstract][Full Text] [Related]
2. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
3. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis.
Brims FJ; Meniawy TM; Duffus I; de Fonseka D; Segal A; Creaney J; Maskell N; Lake RA; de Klerk N; Nowak AK
J Thorac Oncol; 2016 Apr; 11(4):573-82. PubMed ID: 26776867
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
[TBL] [Abstract][Full Text] [Related]
5. Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma.
Alnajar A; Kareff SA; Razi SS; Rao JS; De Lima Lopes G; Nguyen DM; Villamizar N; Rodriguez E
JAMA Netw Open; 2023 Mar; 6(3):e234261. PubMed ID: 36951862
[TBL] [Abstract][Full Text] [Related]
6. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
[TBL] [Abstract][Full Text] [Related]
7. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
[TBL] [Abstract][Full Text] [Related]
8. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma.
Zhang Y; Li R; Gu Y; LiZhu Y; Liu X; Zhang S
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557076
[No Abstract] [Full Text] [Related]
10. Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.
Linton A; Soeberg M; Broome R; Kao S; van Zandwijk N
Respirology; 2017 Jul; 22(5):978-985. PubMed ID: 28139858
[TBL] [Abstract][Full Text] [Related]
11. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
Koyuncu A; Koksal D; Ozmen O; Demirag F; Bayiz H; Aydogdu K; Berkoglu M
J Cancer Res Ther; 2015; 11(1):216-22. PubMed ID: 25879365
[TBL] [Abstract][Full Text] [Related]
13. Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.
Pelosi G; Papotti M; Righi L; Rossi G; Ferrero S; Bosari S; Calabrese F; Kern I; Maisonneuve P; Sonzogni A; Albini A; Harari S; Barbieri F; Capelletto E; Catino AM; Cavone D; De Palma A; Fusco N; Lunardi F; Maiorano E; Marzullo A; Novello S; Papanikolaou N; Pasello G; Pennella A; Pezzuto F; Punzi A; Prisciandaro E; Rea F; Rosso L; Scattone A; Serio G
J Thorac Oncol; 2018 Nov; 13(11):1750-1761. PubMed ID: 30249391
[TBL] [Abstract][Full Text] [Related]
14. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
15. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
16. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
[TBL] [Abstract][Full Text] [Related]
17. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
[TBL] [Abstract][Full Text] [Related]
18. Clinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly.
Pan D; Wang M; Liu W; Li Y; Sang L; Chang B
BMC Gastroenterol; 2022 Jun; 22(1):292. PubMed ID: 35681152
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].
Mlika M; Lamzirbi O; Limam M; Mejri N; Ben Saad S; Chaouch N; Ben Miled K; Marghli A; Mezni F
Rev Pneumol Clin; 2018 Dec; 74(6):427-435. PubMed ID: 30293912
[TBL] [Abstract][Full Text] [Related]
20. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
